The effect of human adrenomedullin on cere bral circulation was investigated in dogs in vivo and in vitro, Bolus administration of adrenomedullin or its ho mologous peptides, calcitonin gene-related peptide (CORP) and amylin, into the vertebral artery induced a dose-dependent increase in vertebral blood flow, The po tencies of adrenomedullin and CORP were similar and approximately 100 times more than that of amylin, The effects of adrenomedullin and CORP were inhibited by CORPs_ 3 7, an antagonist of CORP. In contrast to sub stance P, adrenomedullin did not induce an increase in blood flow after prior administration of CORP. Pretreat ment with either NG-nitro-L-arginine methyl ester or in domethacin did not affect the adrenomedullin-induced in-Abbreviations used: CGRP, calcitonin gene-related peptide; L-NAME, NG-nitro-L-arginine methyl ester; PGF2«, prostaglan din F2«.
Adrenomedullin is a recently discovered 52amino acid peptide that was isolated from human pheochromocytoma tissue on the basis of its ability to increase platelet cyclic AMP concentration (Ki tamura et aI., 1993a) . A cDNA encoding this pep tide has been isolated and sequenced from human and rat tissue (Kitamura et aI., 1993b; Sakata et aI., 1993) . Adrenomedullin has an intramolecular disul fide bond and shows slight homology to calcitonin gene-related peptide (CORP) (Amara et aI., 1982; Rosenfeld et aI., 1983) , a potent hypotensive and vasodilator peptide, as well as to amylin (Cooper et aI., 1987) . Adrenomedullin is synthesized in the normal adrenal medulla, lung, and kidney, but not in the central or peripheral nervous system (Kita mura et aI., 1993a) . A recent study using rat, bo vine, porcine, and human cultured vascular endo thelial cells suggested that vascular endothelial cells have higher levels of adrenomedullin mRNA than adrenal gland, constitutively secret adrenomedullin (Sugo et aI., 1994) . Endothelial cells from several vascular beds including bovine brain capillary were involved. The concentration of adrenomedullin is relatively high in the plasma of healthy humans, and adrenomedullin appears to contribute to the regula tion of general blood flow as a circulating vasodila tor and hypotensive agent (Kitamura et aI., 1993; Sugo et al., /994a ). It is not clear whether the va sodilator effects of adrenomedullin and CORP are mediated through the same receptors. Although the effects of CORP on cerebral circulation and arteries have been studied (Suzuki et aI., 1989; Suzuki, 1993) , those of adrenomedullin remain unknown. Amylin, a 37-amino acid protein that is expressed primarily in pancreatic �-cells and is co secreted from these cells with insulin in response to stimu lation by nutrients such as glucose and arginine (Bhogal et ai., 1993) , also exhibits vasodilator ac tivity (Brain et ai., 1990; Young et ai., 1991) , but the effect of amylin on the cerebral circulation also has not been studied.
We have now compared the effects of human adrenomedullin, CGRP, and amylin on cerebral cir culation in dogs.
METHODS

Preparation of animals
All protocols and surgical procedures were approved by the Institute for Laboratory Animal Research, Nagoya University School of Medicine.
Mature mongrel dogs of both sexes, with body masses of 8-14 kg, were studied. All procedures and angiograms were performed while the animals were anesthetized with sodium pentobarbital (25 mg/kg body mass, i.v.). The an imals were intubated and respiration was controlled through tracheal tubes with room air delivered by a res pirator. The ventilation rate (-12 cycles/min) and tidal volume (20 ml/kg) were adjusted to maintain arterial blood gas concentrations and pH within normal physio logical limits. Body temperature was maintained at 37-38°C with a heating pad. A catheter was placed in the left femoral artery to monitor the MABP and heart rate. A slow, continuous saline infusion was maintained to pre vent dehydration.
Measurement of vertebral artery blood flow
Vertebral artery blood flow was determined with a short extracorporeal loop constructed between the femo ral and vertebral arteries. An electromagnetic flow probe (model MFV-llOO; Nihon Kohden, Tokyo, Japan) was used to measure blood flow from the femoral to the ver tebral artery in the extracorporeal fistula. Peptides were infused into the femoral-vertebral arterial loop in 50 fLl of physiological saline for 5 s. Heparin sodium (1 ,000 U/kg) was administered intravenously to prevent coagulation.
The mechanism of action of adrenomedullin was inves tigated by continuously infusing NG-nitro-L-arginine methyl ester (L-NAME) (1 00 fLg/ml/min) or indomethacin (10 fLg/ml/min) for 10 min before injection of adreno medullin. These concentrations were determined from the preliminary experiments and literatures. Infusion of this concentration of L-NAME inhibited the vasodilator effect induced by 10 pmol of substance P. In addition, a competitive antagonist for CORP receptor, CORPg• 3 7 (10 nmol), was injected simultaneously with adrenomedullin into the vertebral artery shunt. The effects of adreno medullin and CORP, or substance P and CORP, were also examined.
The percentage change in vertebral artery blood flow was calculated from [(blood flow after treatmentlblood flow before treatment) -IJ x 100%, as described previ ously (Asano et aI., 1987; Suzuki et aI., 1988) .
Measurement of vascular diameter
The internal diameter of the basilar artery was deter mined by vertebral angiography in dogs prepared as de scribed previously herein. The right femoral artery was exposed with sterile operative techniques, and a 5-French catheter was inserted into the femoral artery and elon gated to the vertebral artery. A control angiogram was J Cereb Blood Flow Me/ab. Vol. 15. No.5. 1995 performed with 3 ml of 65% meglumine iothalamate at a fixed magnification. Angiograms were then performed at 5, 10, 15, 20, 30, 45, 60, 90 , and 120 min after the injection of I ml of physiological saline or adrenomedullin (dis solved in saline immediately before injection) into the cis terna magna through a spinal needle (no. 22). The pH of all test solutions was virtually the same as that of saline alone. Solutions were injected gently (l mllmin) into the cisterna magna only after the same volume of CSF had been gently withdrawn, to maintain the intracranial pres sure as constant as possible. The diameter of the basilar artery was measured with a computerized image analysis system (Image 1.27, Macintosh Hcx).
Assay of cyclic AMP concentration in CSF and plasma
After administration of 100 pmol or 1 nmol of adreno medullin into the vertebral artery or cisterna magna, plasma or 0.5 ml of CSF samples, respectively, were col lected periodically and stored at -80°C until assayed for cyclic AMP with a commercial radioimmunoassay kit.
Preparation of arterial rings
Mature mongrel dogs were anesthetized by intravenous injection of sodium pentobarbital and exsanguinated via the femoral artery. The basilar and middle cerebral arter ies were rapidly removed into ice-cold oxygenated Krebs Henseleit solution (l 15 mM NaCI, 4.7 mM KCI, 2.5 mM CaCI2, 1.2 mM MgCI2, 2.5 mM NaHC0 3 , 1.2 mM KH2P04, and 10.0 mM' glucose). After removal of the arachnoid membrane and connective tissue, each artery was cut into 5-mm segments with the aid of a dissecting microscope. The arterial rings were vertically fixed be tween L-shaped wires in a tissue bath of 20-ml capacity, and the upper wire was connected by a silk thread to the lever of a force-displacement transducer (Sanei, T7-8-240). The rings were suspended under a resting tension of 1 g in Krebs-Henseleit solution maintained at 37°C. The solution was continuously aerated for 90 min before the start of the experiments. Isometric tensions were re corded on a polygraph.
Measurement of vasorelaxation
Although adrenomedullin and CORP reduced the rest ing tension of arterial rings, the quantitation of the va sorelaxant effect of each peptide was examined in rings that had been precontracted. The application of I fLM prostaglandin F20< (POF20<) resulted in a stable contrac tion. Peptides were added cumulatively to the tissue bath to obtain a concentration-response curve. Care was taken that the response to a particular peptide concentra tion had reached a plateau before the subsequent relax ation was quantified. Responses were expressed as a per centage of the maximal relaxation of the same arterial ring induced by 100 fLM papaverine.
The endothelium was mechanically removed from some arterial rings with a fine wire. The presence or ab sence of endothelium was functionally confirmed by the application of substance P or acetylcholine before exper iments.
Materials
Human adrenomedullin, human amylin, human ex-CORP, CORPg_ 3 7, and substance P were obtained from Peptide Institute (Osaka, Japan). L-NAME was from Cal biochem (La Jolla, CA, U.S.A.) and indomethacin was from Sigma (St. Louis, MO, U.S.A.). The cyclic AMP radioimmunoassay kit was obtained from Yamasa Shoyu (Choshi, Japan). All other chemicals were reagent grade.
Statistical analysis
Data are expressed as means ± SD and were analyzed by analysis of variance, followed by Scheffe's F test, Stu dent's t test, or the Wilcoxon signed-rank test. A p value of < 0.05 was considered statistically significant.
RESULTS
Vertebral artery blood flow
After initial baseline values for vertebral artery blood flow (19.8 ± 4.3 to 24.3 ± 8.4 ml/min) were obtained, changes in flow were measured continu ously for 10 min after a single injection of vehicle (saline) or peptide into the vertebral artery. A single injection of vehicle into the vertebral artery pro duced no significant change in blood flow from baseline. Direct bolus injection of adrenomedullin (1 pmol-I nmol), CGRP (10 pmol-I nmol), or amy lin (100 pmol-1O nmol) produced a dose-dependent increase in vertebral artery blood flow (Figs. 1 and 2). The increase in blood flow induced by 1 nmol of adrenomedullin was maximal (58 ± 13% ml/min of control) at 30 s and remained apparent for 3 min (Fig. 1 ). The increases in vertebral blood flow in duced by 1 nmol of CGRP and 10 nmol of amylin were maximal (70 ± 12% mllmin and 53 ± 8%, re spectively) at 20 s and remained apparent for 3 and saline; 24.0 ± 8.4 ml/min (n = 8),1 pmol adrenomedullin 19.8 ± 4.3 ml/min (n = 6), 10 pmol adrenomedullin 21.1 ± 3.6 ml/min (n = 8),100 pmol adrenomedullin 21.1 ± 7.4 ml/min (n = 8), 1 nmol adrenomedullin 20.6 ± 6.7 ml/min (n = 8).
Values are means ± SD for the number of animals indicated in parentheses. 'p < 0.05, "p < 0.01 versus control. by 1 pmol, 10 pmol, 100 pmol, and 1 nmol adrenomedullin from baseline values are 19.8 ± 4.4 at 20 s from 19.8 ± 4.3 mllmin (n = 6), 25.1 ± 3.6 at 20 s from 21.1 ± 3.6 ml/min (n = 8), 28.9 ± 11.0 at 20 s from 21.1 ± 7.4 ml/min (n = 8), and 32.6 ± 11.2 at 30 s from 20.6 ± 6.7 ml/min (n = 8), respectively. Maximal values by 10 pmol, 100 pmol, and 1 nmol CGRP from baseline valu!'!s are 24.7 ± 1.9 at 20 s from 20.2 ± 1.5 ml/min (n = 6), 30.2 ± 3.1 at 20 s from 21.8 ± 2.9 mllmin (n = 5), and 39.2 ± 11.9 at 20 s from 23. 2 ± 7.8 ml/min (n = 6), respectively. Maximal values by 100 pmol, 1 nmol, and 10 nmol amylin from baseline values are 20.2 ± 3.7 at 20 s from 18.5 ± 3.7 ml/min (n = 6),24.8 ± 5.7 at 20 s from 19.3 ± 4.7 ml/min (n = 6), and 27.2 ± 12.3 at 20 s from 16.8 ± 6.3 ml/min (n = 5), respectively. Values are means ± SD for the number of animals indicated for each point.
2 min, respectively. No significant changes in MABP or heart rate were detected after administra tion of adrenomedullin or amylin at each of the doses tested, whereas 1 nmol of CGRP decreased MABP from 138.3 ± 9. I to 98.8 ± 18.2 mm Hg (n = 6) at 20s with increased heart rate from 128.2 ± 10 to 140.2 ± 24.1 beats/min (n = 6). The vasodilator potency of amylin was � 100 times less than that of adrenomedullin or CGRP.
The blood flow response to 100 pmol of adreno medullin injected 5 min after administration of 1 nmol of CGRP was significantly suppressed, whereas substance P (10 pmol) produced similar re sponses with or without prior administration of 1 nmol of CGRP (Fig. 3) .
Treatment of animals with L-NAME (100 j.Lg/mll min) or indomethacin (10 j.Lg/ml/min) for 10 min be fore administration of adrenomedullin did not mod ify the effect of the peptide on vertebral artery blood flow induced by adrenomedullin (Fig. 4) . The effect of 10 pmol of adrenomedullin or 10 pmol of CGRP on vertebral artery blood flow was inhibited by simulta neous injection of 10 nmol of CGRPS_37 (Fig. 5) . stance P (SP). The maximal effects of 100 pmol of AM and 10 pmol of SP on VBF were assessed alone and 5 min after administration of 1 nmol of CGRP. The increasing effects by CGRP returned to the baseline values until 5 min. Maximal values by 100 pmol adrenomedullin and 10 pmol substance P in the presence of CGRP are 23.6 ± 8.8 from 21.8 ± 8.6 ml/min (n = 5) and 27.8 ± 9.5 from 14.8 ± 4.5 ml/min (n = 4), respectively. Values are means ± SO for the indicated num bers of animals. NS, not significant.
Angiography
Intracisternal Injection of adrenomedullin (100 pmol-l nmol) induced a dose-dependent increase in the internal diameter of the major cerebral arteries, as determined by angiography ( Figs. 6 and 7) . The middle portion of the basilar artery was chosen for quantitative assessment by computerized image analysis of the changes in vascular diameter after administration of vehicle (saline) or adrenomedul lin. The maximal dilation induced by 1 nmol of adrenomedullin was 33.2 ± 13.9% at 15 min, and the extent of dilation remained significant for 90 min (Fig. 7) .
Concentrations of cyclic AMP
Assay of cAMP in CSF showed a significant in crease at 30 min after intracisternal administration of 1 nmol of adrenomedullin (30.2 ± 6.2 pmollml) from control values, but no increase after 100 pmol of adrenomedullin. Assay of cAMP in plasma showed no increase after injection of each dose of adrenomedullin into the vertebral artery at 5, 10, and 15 min.
Vasorelaxant effect of adrenomedullin in vitro
Adrenomedullin (0.1-100 nM) elicited a concen tration-dependent relaxation of the basilar and mid . dIe cerebral arteries that had been precontracted by Vol. 15, No.5. 1995 laxation induced by CGRP was approximately five times that induced by adrenomedullin, whereas amylin did not elicit vasorelaxation (Fig. 8) . The responses to these peptides were not affected by mechanical removal of the endothelium. DISCUSSION We have shown that the direct injection of adrenomedullin into the vertebral artery increased vertebral artery blood flow in dogs. Adrenomedul lin also induced vasodilation in the major cerebral arteries as determined by angiography in vivo, and elicited endothelium-independent relaxation of the basilar and middle cerebral arterial rings in vitro.
Previous studies have examined the effects of adrenomedullin on the cardiovascular system (Per ret et aI., 1993; Ishiyama et aI., 1993) and mesen teric .vascular beds (Nuki et aI., 1993) . It is likely that the potent vasodilator activity of adrenomedul lin in the peripheral vascular system, rather than its mild negative inotropic effect on cardiac function, accounts for the marked and prolonged systemic Q) 100 The effect of prior administration of indomethacin or L-NAME on the maximal increase in vertebral artery blood flow (VBF) induced by adrenomedullin. Indomethacin (10 fLgl ml) or NG-nitro-L-arginine methyl ester (L-NAME) (100 fLg/ml) was continuously infused at a speed of 1 ml/min into the vertebral artery shunt for 10 min before administration of adrenomedullin (AM). Pretreatment with indomethacin slightly increased the vertebral artery blood flow from 18.5 ± 4.2 to 19.3 ± 3.5 ml/min (n = 8). Maximal values by 10 pmol adrenomedullin after infusion of indomethicin was 24.6 ± 4.0 19.3 ± 3.5 ml/min (n = 8). Pretreatment with L-NAME de creased the vertebral artery blood flow from 20.2 ± 7.7 to 12.3 ± 3.3 mllmin (n = 4). Maximal values by 100 pmol adrenomedullin after infusion of L-NAME was 21.0 ± 4.9 from 12.3 ± 3.3 ml/min (n = 4). Values are means ± SO for the indicated number of animals. NS, not significant. (AM) (from 19.0 ± 2.8 to 19.2 ± 2.8 ml/min, n = 6) or CGRP (from 19.0 ± 2.5 to 19.5 ± 2.9 ml/min, n = 6). Values are means ± SO (n = 6).
vasodepressor response to this peptide in rats (Per ret et al., 1993) . Adrenomedullin-induced vasodila tion may be attributable to stimulation of cyclic AMP synthesis in vascular smooth-muscle cells. A recent study with 1 2 5 I-labeled rat adrenomedullin demonstrated the presence of a single class of high affinity binding sites for adrenomedullin in cultured vascular smooth-muscle cells from rat thoracic aorta (Eguchi et al., 1994) . These receptors appear to be coupled to adenylate cyclase. Accumulation of intracellular cyclic AMP by CGRP is known to activate A TP-sensitive K + channels in the cerebral arteries (Kitazono et al., 1993) . Our observation that intracisternal administration of adrenomedullin increased the concentration of cyclic AMP in CSF supports this hypothesis. This increase of cyclic AMP in CSF may partly reflect the increase in vas cular smooth muscle, because efflux of cyclic nu cleotides from cells has been observed (Fiscus et al., 1987) . Pretreatment with L-NAME or indomethacin did not affect adrenomedullin-induced vasodilation, which suggests that the vasodilator action of adrenomedullin is not dt:;pendent on nitric oxide for mation, either in the endothelium or in the parasym pathetic nerve terminals that innervate the blood vessels (Nozaki et aI., 1993) or on vasoactive pros taglandins synthesized via the cyclooxygenase pathway. However, it has been demonstrated that vasodilation induced by CGRP and substance P is endothelial-dependent in pial arterioles of mouse, as responses to CGRP and substance P were blocked by endothelial injury (Rosenblum et al., 1993). This evidence supports the claim that there may possibly be species or size dependency for ef fects of adrenomedullin. A truncated version of adrenomedullin lacking the first 12 amino acid residues, adrenomedullinl3_ 52, shows similar vasodepressor activity to the full length molecule (Perret et aI, 1993; Hao et aI., 1994; Lin et aI., 1994) . This fragment of adrenomedullin, which shows structural homology to CGRP, thus appears necessary and sufficient to produce a sys temic vasodepressor response. However, the pres ence or concentration of adrenomedullin in various tissues has been determined using an antibody to adrenomedullin-( 1-12) so far (Kitamura et aI., 1993) . This result still leaves open the possibility that free fragments of adrenomedullin not previously mea sured mediate several biological activities. Studies with CGRP fragments, analogs, and homologs have also suggested that the carboxyl-terminal portion of CGRP is important for binding and biological activ ity (Dennis et aI., 1989 (Dennis et aI., , 1990 . We have now shown that prior administration of CGRP inhibited the adrenomedullin-induced increase in vertebral artery blood flow but had no effect on the increase in blood flow induced by substance P. Furthermore, the competitive CGRP antagonist CGRPS_37 inhib ited the effects of both CGRP and adrenomedullin. Together, these results suggest that adrenomedul lin-induced vasodilation is mediated by CGRP receptors. Nuki et al. (1993) showed that the vasodilator ac tivity of adrenomedullin was approximately one tenth that of CGRP in rat mesenteric vascular beds. We have shown that the extent of vasorelaxation induced by adrenomedullin in vitro was approxi mately one-tenth of that induced by CGRP. Amylin showed no activity. The maximal effects on verte bral artery blood flow in vivo were similar for all three peptides, although the potency of amylin was approximately one-hundredth of that of CGRP or adrenomedullin. The difference in responsiveness between in vivo and in vitro studies may be ex plained by influences of several general and local factors. As one of such explanations, the vertebral blood flow study compared with angiographic and isometric tension studies includes extracranial con tamination reflecting flow changes in skeletal mus cle and meninges. The absolute baseline values of vertebral artery blood flow in this study are almost similar to those obtained with a noncannulating electromagnetic flow probe directly placed around the vertebral ar tery (Asano et aI., 1989) , although it may be sug gested that the tubing resistance of a short extra corporeal loop decreases the vertebral arterial blood flow and alters vascular reactivity to exoge nous vasoactive peptides. We used the hard rubber material for tubing to prevent the blood flow from being influenced by the changes in diameters of tub ing following blood pressure. If we could investi gate the influence of adrenomedullin-like CGRP (Suzuki et al., 1989) on regional cerebral blood flow, the data in vertebral artery blood flow would be more meaningful in interpreting the changes in cerebral blood flow. The observation that, like CGRP (Kitazono et aI., 1993; Oyama et aI., 1993) , adrenomedullin induced significant vasodilation in major cerebral vessels indicates that adrenomedul lin regulates cerebral blood flow in addition to the peripheral vascular system. CGRP is widely distributed throughout the cen tral and peripheral nervous system (Suzuki, 1993) . It is present in the sensory nerve fibers that inner vate blood vessels and functions to adjust the local cerebral blood flow in response to antidromic acti vation or axon reflex after receipt of nociceptive signals on the vascular wall (McCulloch et aI., 1986; Saito et aI., 1989) . Although adrenomedullin and amylin have not been detected in the brain so far (Kitamura et aI., 1993a) , active production of adrenomedullin has recently been found in cultured endothelial cells from bovine brain capillary (Sugo et aI., 1994) . We therefore suggest that CGRP, adrenomedullin, and amylin belong to the same peptide family and that adrenomedullin and amylin act at the same receptors as CGRP. Adrenomedul lin appears to function mainly as a circulating hor mone or a local vasodilator from endothelial cells, whereas CGR� functions as a neuropeptide.
